Access and Affordability

For more than 10 years, CSL Behring has supported the World Federation of Hemophilia (WFH) to improve the diagnosis and treatment of people with bleeding disorders around the world.

In addition to its financial support for the organisation’s work, CSL Behring is a program sponsor and donor to the WFH’s Global Alliance for Progress (GAP) Program, a worldwide initiative seeking to save and improve the quality of life of people with bleeding disorders.

In May 2022, CSL Behring announced a new partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program. Commencing in 2023, CSL Behring will donate a total of 500 million international units (IUs) of coagulation factor therapy to the WFH, over five years, including product specifically manufactured for the purposes of being donated, creating consistent and reliable access to treatment for people living with bleeding disorders in more than 50 developing countries.

By manufacturing product specifically for the purposes of donation, the coagulation factor therapy will have a standard shelf life of three years, thus enabling greater access to these life-saving therapies for people around the world. The donated product will be delivered twice a year for five years.

CSL Behring also provides financial support for logistics costs and training programs designed to address unmet needs for people living with haemophilia in developing countries who are undiagnosed, untreated, or undertreated. CSL Behring’s contributions to the WFH Humanitarian Aid program make life-changing improvement to people with no access to care for bleeding disorders.

CSL has made a systematic commitment to contribute products to WFH. Manufactured specifically for WHF, the product was shipped from CSL Behring’s Marburg, Germany facility to the WFH site in Belgium. The product is then distributed, at WFH’s discretion, to over 50 countries based on need. CSL’s contribution is especially important in providing and increasing prophylaxis therapy for children and adults, which also can help decrease the number of acute bleeding incidents and improve surgery outcomes.

For more details on CSL’s patient and product impact as a result of the partnership see our detailed case study - Driving positive outcomes for people with bleeding disorders in developing countries - in the Healthier Communities section of our Annual Report.

CSL Seqirus supports the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework which aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to an influenza pandemic including vaccines, antivirals and diagnostics. CSL Seqirus makes an annual financial contribution and has also committed 10% of influenza vaccine output in real time to the WHO for deployment to developing countries in the event of a pandemic emergency.

To further enhance our ability to protect public health, CSL Seqirus entered into a five-year partnership with Pandemic Institute in Liverpool, UK, in 2023, which will deliver on a number of joint projects, such as modelling the spread and impact of avian influenza ahead of a potential pandemic.

CSL recognises the importance of collaborating with patient advocacy organisations to help bridge health equity gaps and provide access to medicines through resources and solutions. CSL Behring’s donation to patient advocacy organisations aligns with its overall strategic business goals and principles of general social responsibility, by funding support and education, and through advocacy that help improve health outcomes.
CSL provides funding support through annual charitable donations to Hereditary Angioedema International (HAEi) and the Jeffrey Model Foundation.
CSL’s donation to the HAEi supports education, technology and advocacy activities encapsulated in the four strategic pillars for HAEi, including; Member Organisation Development, ACARE: Collaboration with the Global Physician/Scientific Community, HAEi Youngster’s Community, and HAEi Initiated Data Driven Advocacy Research.

In addition, our charitable donation supports HAEi’s Regional Patient Advocates (RPAs) in HAE patient identification and outreach, support, training and additional HAEi initiatives in developed and developing countries, including in Europe, Middle East, Africa, Asia Pacific, Southeastern Asia, America, South America and Mexico.

The Jeffrey Modell Foundation is a devoted to early and precise diagnosis, meaningful treatments and, ultimately, cures for those with primary immunodeficiency (PI). CSL Behring has been a partner to this organisation and its important work of creating PI diagnostic and research centres since its inception over 30 years ago.

CSL’s donation supports eleven Jeffrey Modell Diagnostics and Research Centres for Primary Immunodeficiencies. The funding support will provide comprehensive physician education and public awareness campaigns in the areas of early diagnosis, education and public health awareness around access to care, and improved quality of life.
The eleven Jeffrey Modell Diagnostic and Research Centres are in developed and developing countries including Algeria, Egypt, Morocco, Tunisia, Argentina, Brazil, Mexico, Turkey, Austria, Belgium, Switzerland, Japan, China and Australia.

These centres offer advanced diagnostic evaluations to patients with suspected primary immune deficiencies and our support helps CSL to deliver on our promise to PI patients. In Africa, it’s estimated that the diagnosis rate of PI, a life-threatening condition, is only about 0.3 percent.

A unique partnership between Australia and Papua New Guinea to donate antivenoms and help save the lives of people bitten or stung by venomous snakes and marine creatures has been extended for a further three years. The extension builds on a highly successful program that has been in operation since 2018 and is estimated to have saved over 2,000 lives.

PNG has one of the highest snakebite rates in the world, with around 1,000 people believed to die from snakebite each year. PNG’s highly venomous snakes, including the Papuan taipan and death adder, are closely related to Australian snakes and thus bites from these snakes can be treated using antivenoms manufactured by CSL Seqirus, with funding from the Australian Government.

Each year, CSL Seqirus donates up to 600 vials of antivenom to the PNG National Department of Health, which is then distributed around PNG via the PNG Snakebite Partnership, a collaboration between CSL, NDoH, the Australian High Commission Port Moresby, and, as of 2024 our new in-country distribution partner St John’s Ambulance PNG. The 600 vial annual donation more than triples the annual supply of antivenom that was available in-country before the partnership began and comes at no cost to this developing nation.

Since the inception of the Partnership, CSL has donated almost 3,000 vials of antivenom, which have been distributed to 50 health centres across 13 provinces. In addition, Australian Government support has allowed over 1,500 health workers from over 70 facilities to be trained in snakebite patient management. This combination of antivenom access and improved training is estimated to have led to over 2,000 lives being saved, representing a significant public health contribution to one of Australia’s closest neighbours.